BR112022012917A2 - Composição tópica, kit, métodos para tratar ou melhorar um distúrbio da pele, de mucosa, de cavidade corporal, método para tratar uma condição relacionada a jak, método para tratar ou prevenir um distúrbio dermatológico, e, uso da composição tópica - Google Patents

Composição tópica, kit, métodos para tratar ou melhorar um distúrbio da pele, de mucosa, de cavidade corporal, método para tratar uma condição relacionada a jak, método para tratar ou prevenir um distúrbio dermatológico, e, uso da composição tópica

Info

Publication number
BR112022012917A2
BR112022012917A2 BR112022012917A BR112022012917A BR112022012917A2 BR 112022012917 A2 BR112022012917 A2 BR 112022012917A2 BR 112022012917 A BR112022012917 A BR 112022012917A BR 112022012917 A BR112022012917 A BR 112022012917A BR 112022012917 A2 BR112022012917 A2 BR 112022012917A2
Authority
BR
Brazil
Prior art keywords
treatment
topical composition
disorder
jak
mucosal
Prior art date
Application number
BR112022012917A
Other languages
English (en)
Portuguese (pt)
Inventor
Elliott Russell
Hazot Yohan
Winckle Gareth
Margulis Ariel
Original Assignee
Vyne Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vyne Therapeutics Inc filed Critical Vyne Therapeutics Inc
Publication of BR112022012917A2 publication Critical patent/BR112022012917A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112022012917A 2019-12-31 2020-12-31 Composição tópica, kit, métodos para tratar ou melhorar um distúrbio da pele, de mucosa, de cavidade corporal, método para tratar uma condição relacionada a jak, método para tratar ou prevenir um distúrbio dermatológico, e, uso da composição tópica BR112022012917A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962955847P 2019-12-31 2019-12-31
US202063066717P 2020-08-17 2020-08-17
US202063086442P 2020-10-01 2020-10-01
US202063086275P 2020-10-01 2020-10-01
PCT/US2020/067612 WO2021138525A1 (en) 2019-12-31 2020-12-31 Topical composition comprising tofacitinib and fingolimod

Publications (1)

Publication Number Publication Date
BR112022012917A2 true BR112022012917A2 (pt) 2022-09-06

Family

ID=74285586

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022012917A BR112022012917A2 (pt) 2019-12-31 2020-12-31 Composição tópica, kit, métodos para tratar ou melhorar um distúrbio da pele, de mucosa, de cavidade corporal, método para tratar uma condição relacionada a jak, método para tratar ou prevenir um distúrbio dermatológico, e, uso da composição tópica

Country Status (9)

Country Link
US (1) US20230037905A1 (cg-RX-API-DMAC7.html)
EP (1) EP4084776A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023509441A (cg-RX-API-DMAC7.html)
AU (1) AU2020417290A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022012917A2 (cg-RX-API-DMAC7.html)
CA (1) CA3163530A1 (cg-RX-API-DMAC7.html)
IL (1) IL294239A (cg-RX-API-DMAC7.html)
TW (1) TW202135825A (cg-RX-API-DMAC7.html)
WO (1) WO2021138525A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010302350B2 (en) 2009-10-02 2015-06-18 Journey Medical Corporation Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US12661407B2 (en) 2010-04-08 2026-06-23 Journey Medical Corporation Compositions, gels and foams with rheology modulators and uses thereof
JP7324210B2 (ja) * 2018-01-31 2023-08-09 ティダブリューアイ・バイオテクノロジー・インコーポレイテッド トファシチニブを含む局所製剤
CN116437921A (zh) * 2020-09-28 2023-07-14 株式会社Lg化学 鞘氨醇-1-磷酸酯受体激动剂的用途
CN120168480A (zh) * 2025-04-17 2025-06-20 四川省医学科学院·四川省人民医院 托法替尼在制备治疗干性年龄相关性黄斑变性的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874794A (en) 1989-04-28 1989-10-17 Lidak Biopharmaceuticals Inflammatory disease treatment
US9474720B2 (en) 2013-11-04 2016-10-25 BioPharmX, Inc. Dosage form comprising an active ingredient and a plurality of solid porous microcarriers

Also Published As

Publication number Publication date
CA3163530A1 (en) 2021-07-08
EP4084776A1 (en) 2022-11-09
WO2021138525A1 (en) 2021-07-08
IL294239A (en) 2022-08-01
TW202135825A (zh) 2021-10-01
AU2020417290A1 (en) 2022-05-26
US20230037905A1 (en) 2023-02-09
JP2023509441A (ja) 2023-03-08

Similar Documents

Publication Publication Date Title
MX2022001607A (es) Composiciones y metodos para tratar la psoriasis y la dermatitis atopica usando prevotella histicola.
MX2026002469A (es) Nuevas moleculas de acido nucleico artificiales
PH12018502634A1 (en) Topical compositions of apremilast
EP4338804A3 (en) Epinephrine spray formulations
CL2023000921A1 (es) Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
CO2018005361A2 (es) Formulaciones inyectables de toxina botulínica y sus métodos de uso que poseen efecto terapéutico o cosmético de larga duración
BR112013026494A2 (pt) composto, composição farmacêutica, método para tratar condição
CO6670567A2 (es) Métodos de tratamiento contra el cáncer pancreático
BR112015001782A2 (pt) método para produzir uma composição para o tratamento de um dente lesionado
BR112014026058A2 (pt) composições para tratamento tópico de infecções microbianas
MX2020012018A (es) Composiciones para el tratamiento de condiciones de la piel.
BR112021021676A2 (pt) Uso de preparação de exossomo de células-tronco mesenquimais para a preparação de composição para o tratamento da doença periodontal
WO2024163641A3 (en) Formulations for treating cancer
MX382357B (es) Métodos y composiciones para tratar infecciones fúngicas cutáneas.
BR112016024621A2 (pt) composições para tratamento bucal
ZA202304965B (en) Combination therapy for treating cancer
WO2023097194A3 (en) Bicyclic therapeutic compounds and methods of use in the treatment of cancer
PH12022552738A1 (en) Compositions comprising nanoparticles, method of making and uses thereof
EP4357334A3 (en) Conjugated oligonucleotide compounds, methods of making and uses thereof
MX2024005303A (es) Formulaciones biotensioactivas para su uso en el cuidado de la piel y el tratamiento de heridas.
WO2024006292A3 (en) Methods of treating cancer
BR112022003659A2 (pt) Composições e métodos de tratamento de doenças vasculares
MX2019011933A (es) Composiciones cosmeticas que contienen sistema enzimatico.
BR112022018770A2 (pt) Composição alogênica compreendendo células t vd1+, dose, e, método de tratamento de uma malignidade mieloide

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]